Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-related adverse events. Insights into biomarkers and mechanisms of response and toxicity to CICB...
Strictly necessary cookies
Strictly necessary cookies must always be activated so that we can save your cookie settings preferences.
If you deactivate this cookie, we will not be able to save your preferences. This means that every time you visit this website you will have to activate or deactivate cookies again.
Third party cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, or the most popular pages.
Leaving this cookie active allows us to improve our website.
Please activate the strictly necessary cookies first so that we can save your preferences!